Fig. 7

Erlotinib has strong therapeutic implications for ARNTL2-high patients in patient-derived xenografts. A, E, I, M Images illustrating the IHC staining for human ARNTL2 in PC-PDX1 (A), PC-PDX2 (E), PC-PDX3(I), and PC-PDX4(M); (B, F, J, N) Tumor growth curves of PC-PDX1 (B), PC-PDX2 (F), PC-PDX3 (J) and PC-PDX4 (N) treated with erlotinib and vehicle. Arrows indicate the day when treatment started; (C, G, K, O) Representative tumor images of erlotinib and vehicle group of PC-PDX1 (C), PC-PDX2 (G), PC-PDX3(K) and PC-PDX4 (O) at the end of treatment; (D, H, L, P) Quantitative analysis of PC-PDX1 (D), PC-PDX2(H), PC-PDX3 (L) and PC-PDX4(P) weight at the end of treatment; All data are presented as the mean ± SEM of triplicate experiments. **p < 0.01; ***p < 0.001 by repeated measures with Student’s t-test